MY131878A - Eplerenone crystalline form exhibiting enhanced dissolution rate - Google Patents

Eplerenone crystalline form exhibiting enhanced dissolution rate

Info

Publication number
MY131878A
MY131878A MYPI20005734A MYPI20005734A MY131878A MY 131878 A MY131878 A MY 131878A MY PI20005734 A MYPI20005734 A MY PI20005734A MY PI20005734 A MYPI20005734 A MY PI20005734A MY 131878 A MY131878 A MY 131878A
Authority
MY
Malaysia
Prior art keywords
eplerenone
dissolution rate
crystalline form
preparing
exhibiting enhanced
Prior art date
Application number
MYPI20005734A
Other languages
English (en)
Inventor
Kathleen P Barton
Mark A Pietz
Daniel R Pilipauskas
Yuen-Lung L Sing
Glenn L Stahl
Joseph J Wieczorek
Chris Y Yan
Thomas B Borchardt
Marlon V Carlos
Subbash Desai
Leonard J Ferro
Henry T Gaud
Scott Ganser
Clay R Little
Partha S Mudipalli
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MY131878A publication Critical patent/MY131878A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes
    • C07J71/0015Oxiranes at position 9(11)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MYPI20005734A 1999-12-08 2000-12-06 Eplerenone crystalline form exhibiting enhanced dissolution rate MY131878A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US16955699P 1999-12-08 1999-12-08
US16980799P 1999-12-08 1999-12-08
US16960899P 1999-12-08 1999-12-08
US16963999P 1999-12-08 1999-12-08
US16969099P 1999-12-08 1999-12-08
US16968299P 1999-12-08 1999-12-08

Publications (1)

Publication Number Publication Date
MY131878A true MY131878A (en) 2007-09-28

Family

ID=27558585

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20005734A MY131878A (en) 1999-12-08 2000-12-06 Eplerenone crystalline form exhibiting enhanced dissolution rate

Country Status (17)

Country Link
EP (1) EP1177204A2 (https=)
JP (1) JP2003516414A (https=)
KR (1) KR100607923B1 (https=)
CN (2) CN1152886C (https=)
AU (1) AU784946B2 (https=)
BR (1) BR0008057A (https=)
CA (1) CA2362669A1 (https=)
CO (1) CO5280211A1 (https=)
EA (1) EA007934B1 (https=)
HU (1) HUP0203032A3 (https=)
IL (3) IL144764A0 (https=)
MX (1) MXPA01008056A (https=)
MY (1) MY131878A (https=)
NO (1) NO20013856L (https=)
NZ (2) NZ530028A (https=)
PE (1) PE20010917A1 (https=)
WO (1) WO2001042272A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072797A1 (en) * 2002-03-20 2004-04-15 Pornanong Aramwit Storage stable eplerenone formulation
US7235655B2 (en) 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
CA2582496A1 (en) 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Improved process for the preparation and purification of eplerenone
ES2566934T3 (es) 2010-05-10 2016-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
WO2017064121A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
CN108059648A (zh) * 2017-12-30 2018-05-22 合肥久诺医药科技有限公司 一种依普利酮溶剂合物及其制备方法
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea
WO2023204729A1 (ru) * 2022-04-19 2023-10-26 Общество с ограниченной ответственностью "Гелеспон" Фармацевтические композиции на основе новой субстанции 4-[2-(1н-имидазол-4-ил)-этилкарбамоил]-бутановой кислоты и способ получения субстанции
CN120754115A (zh) * 2025-05-23 2025-10-10 远大医药(中国)有限公司 一种含依普利酮组合物及其药物制剂、制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
PT944644E (pt) * 1996-12-11 2003-02-28 Searle & Co Processos para a preparacao de esteroides 9,11-epoxi e intermediarios uteis para esse efeito
IL145237A0 (en) * 1999-03-05 2002-06-30 Searle & Co Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease

Also Published As

Publication number Publication date
WO2001042272A3 (en) 2001-11-29
NZ530028A (en) 2005-08-26
WO2001042272A9 (en) 2002-12-12
HUP0203032A2 (hu) 2002-12-28
NO20013856D0 (no) 2001-08-08
IL144764A0 (en) 2002-06-30
MXPA01008056A (es) 2003-07-21
AU2049201A (en) 2001-06-18
CN1377365A (zh) 2002-10-30
IL144764A (en) 2007-08-19
CN1152886C (zh) 2004-06-09
KR100607923B1 (ko) 2006-08-04
HK1050536A1 (en) 2003-06-27
CN1557833A (zh) 2004-12-29
EP1177204A2 (en) 2002-02-06
AU784946B2 (en) 2006-08-03
CA2362669A1 (en) 2001-06-14
KR20010112261A (ko) 2001-12-20
NO20013856L (no) 2001-10-08
HUP0203032A3 (en) 2003-04-28
PE20010917A1 (es) 2001-09-10
CO5280211A1 (es) 2003-05-30
EA200100871A1 (ru) 2002-04-25
NZ513961A (en) 2004-02-27
BR0008057A (pt) 2002-04-23
JP2003516414A (ja) 2003-05-13
IL176511A (en) 2007-08-19
EA007934B1 (ru) 2007-02-27
WO2001042272A2 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
MY131878A (en) Eplerenone crystalline form exhibiting enhanced dissolution rate
CA2366268A1 (en) Pharmaceutical compositions for cns and other disorders
CA2366911A1 (en) Compositions for improving fertility
CA2782529C (en) Morphinan derivatives for the treatment of drug overdose
DK0991646T3 (da) Itraconazol med forbedret opløselighed, fremgangsmåde til fremstilling deraf, og et farmaceutisk præparat til oral administrering og indeholdende dette
CA2688708A1 (en) Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
NZ514574A (en) Novel method of treatment
WO2003047519A3 (en) 'compressed annular tablet with molded triturate tablet for oral and intraoral'
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
RU2002105377A (ru) Ксенон-антагонист nmda
PT1200103E (pt) Xénon como antagonista de nmda para neuroprotecção
CA2508611A1 (en) Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
MY143571A (en) Eplerenone crystalline form
CA2378834A1 (en) Pyrazinones, compositions containing such compounds
IL148777A (en) Mirtazepine oral oral administration unit
CA2325014A1 (en) 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5h-benzo[5,6]cyclohepta[1,2-b]pyridine oral compositions
EP1505072A3 (en) Eplerenone crystalline form exhiniting enhanced dissolution rate
AP2001002367A0 (en) Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2,2]oct-3-yl)-5-isopropyl-2-methoxybenzyl)-ammoniumchloride as nk-1-receptor antagonists.
AU3278800A (en) Pharmaceutical composition containing desoxypeganine for the treatment of drug dependence
MXPA01012936A (es) Composicion farmaceutica que contiene sibutramina y orlistat.
JP2003523385A5 (https=)
CA2395458A1 (en) Use of bioactive metabolites of gepirone for the treatment of psychological disorders
UA66925C2 (uk) Поліморфні форми кристалічного цитрату азабіцикло[2.2.2]-октан-3-аміну, спосіб їх одержання, фармацевтична композиція та спосіб лікування блювання
AU2907800A (en) Pharmaceutical composition containing desoxypeganine for the treatment of alcoholism
EP1580193A3 (en) Eplerenone crystalline form